Ventilation and aerosolized drug delivery to the paranasal sinuses using pulsating airflow a preliminary study

Rhinology

Volumn 47, Issue 4, 2009, Pages 405-412

  Möller, Winfried ^a   Schuschnig, Uwe ^b   Meyer, Gabriele ^c   Häussinger, Karl ^c   Keller, Manfred ^b   Junge Hülsing, Bernhard ^d   Mentzel, Heribert ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b PARI GmbH   (Germany)

^c ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^d Starnberg Hospital   (Germany)

Author keywords

Krypton gas inhalation; Paranasal sinus ventilation; Pulsating aerosol; Scintigraphy

Indexed keywords

KRYPTON; PENTETATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LUNG VENTILATION; MALE; MIDDLE AGED; PARANASAL SINUS; PULSATILE FLOW; SCINTILLATION CAMERA;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADULT; GAMMA CAMERAS; HUMANS; KRYPTON; MALE; MIDDLE AGED; PARANASAL SINUSES; PULMONARY VENTILATION; PULSATILE FLOW; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M PENTETATE;

EID: 72849116639     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhin08.180     Document Type: Article

References (40)

1. Van Cauwenberge P, Watelet JB. Epidemiology of chronic rhinosinusitis. Thorax 2000; 55: 20S-1.
2. MedlinePlus. Sinusitis Fact Sheet, January 2006. Washington, DC: National Institute of Allergy and Infectious Diseases; 2006 [updated 2006; cited]; Available from: http://www.niaid.nih.gov/factsheets/sinusitis.htm.
3. Fokkens W, Lund V, Mollol J. The European Position Paper on Rhinosinusitis and Nasal Polyps (EP30S) group. Rhinology 2007; 45: Suppl 20: 1-137.
4. Epstein VA, Kern RC. Invasive fungal sinusitis and complications of rhinosinusitis. Otolaryngol Clin North Am 2008; 41: 497-524.
5. Clement PA. Definitions of sinusitis. Acta Otorhinolaryngol Belg 1997; 51: 201-2003.
6. Baraniuk J, Maibach H. Pathophysiological classification of chronic rhinosinusitis. Respir Res 2005; 6:149.
7. 7. Armengot M, Juan G, Barona R, Garin L, Basterra J. Immotile cilia syndrome: nasal mucociliary function and nasal ciliary abnormalities. Rhinology 1994; 32: 109-111. (Pubitemid 24344335)
8. Min YG, Shin JS, Choi SH, Chi JG, Yoon CJ. Primary ciliary dyskinesia: ultrastructural defects and clinical features. Rhinology 1995; 33: 189-193.
9. 9. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia - Diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169: 459-467. (Pubitemid 38187117)
10. Pinto JM, Hayes MG, Schneider D, Naclerio RM, Ober C. A genomewide screen for chronic rhinosinusitis genes identifies a locus on chromosome 7q. Laryngoscope 2008; 2008; 118: 20672067.
11. 11. Tarhan E, Coskun M, Cakmak O, Celik H, Cankurtaran M. Acoustic rhinometry in humans: accuracy of nasal passage area estimates, and ability to quantify paranasal sinus volume and ostium size. J Appl Physiol 2005; 99: 616-623. (Pubitemid 41061157)
12. 12. Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 2001; 51: 5-19. (Pubitemid 32763069)
13. Sato Y, Hyo N, Sato M, Takano H, Okuda S. Intra-nasal distribution of aerosols with or without vibration. Z Erkr Atmungsorgane 1981; 157: 276-280.
14. 14. Hyo N, Takano H, Hyo Y. Particle deposition efficiency of therapeutic aerosols in the human maxillary sinus. Rhinology 1989; 27: 17-26. (Pubitemid 19088130)
15. Suman JD. Nasal drug delivery. Expert Opin Biol Th 2003; 3: 519523.
16. 16. Saijo R, Majima Y, Hyo N, Takano H. Particle deposition of therapeutic aerosols in the nose and paranasal sinuses after transnasal sinus surgery: a cast model study. Am J Rhinol 2004; 18: 1-7. (Pubitemid 38351407)
17. 17. Maniscalco M, Sofia M, Weitzberg E, Lundberg JO. Sounding airflow enhances aerosol delivery into the paranasal sinuses. Eur J Clin Invest 2006; 36: 509-513. (Pubitemid 43876132)
18. 18. Kimbell JS, Segal RA, Asgharian B, et al. Characterization of Deposition from Nasal Spray Devices Using A Computational Fluid Dynamics Model of The Human Nasal Passages. J Aerosol Med 2007; 20: 59-74. (Pubitemid 46542937)
19. 19. Gosepath J, Mann WJ. Current Concepts in Therapy of Chronic Rhinosinusitis and Nasal Polyposis. ORL 2005; 67: 125-136. (Pubitemid 41022619)
20. Mainz J, Mentzel HJ, Schneider G, et al. Sinu-nasal inhalation of Dornase alfa in CF. Results of a double-blind placebo-controlled pilot trial. J Cystic Fibrosis 2008; 7: S27.
21. Kauf H. Eindringvermögen von Aerosolen in Nebenräume [Penetration ability of aerosols into secondary spaces]. Eur Arch Otorhinolaryngol 1968; 190: 95-108.
22. Böhm A, Luber M, Mentzel H, Knoch M. Investigating Drug Delivery to the Sinuses: An In Vitro Deposition Study Using a Nasal Cast Model. Respiratory Drug Delivery IX 2004; 3: 601-604.
23. Möller W, Schuschnig U, Meyer G, Mentzel H, Keller M. Ventilation and drug delivery to the paranasal sinuses: studies in a nasal cast using pulsating airflow. Rhinology 2008; 46: 213-220.
24. Schuschnig U, Keller M, Klopfer E, et al. Drug Delivery to the Nasal and Paranasal Cavities - Critical Cast Dimensions and Aerosol Dynamics. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory Drug Delivery 2008 Arizona. Scottsdale, Arizona, USA: Virginia Commonwealth University; 2008. p.227-238.
25. Wagner HN, Szabo Z, Buchanan J. Principles of nuclear medicine. 2nd ed. Philadelphia: Saunders; 1995.
26. 26. Paulsson B, Dolata J, Larsson I, Ohlin P, Lindberg S. Paranasal sinus ventilation in healthy subjects and in patients with sinus disease evaluated with the 133-xenon washout technique. Ann Otol Rhinol Laryngol 2001; 110: 667-674. (Pubitemid 32634906)
27. 27. Paulsson B, Lindberg S, Ohlin P. Washout of 133-xenon as an objective assessment of paranasal sinus ventilation in endoscopic sinus surgery. Ann Otol Rhinol Laryngol 2002; 111: 710-717. (Pubitemid 34864250)
28. Schroeter JD, Kimbell JS, Gross EA, et al. Application of Physiological Computational Fluid Dynamics Models to Predict Interspecies Nasal Dosimetry of Inhaled Acrolein. Inhal Toxicol 2008; 20: 227-243.
29. Suman JD, Laube BL, Dalby R. Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. Pharm Res 1999; 16: 1648-1652.
30. 30. Inanli S, Ozturk O, Korkmaz M, Tutkun A, Batman C. The effects of topical agents of fluticasone propionate, oxymetazoline, and 3% and 0.9% sodium chloride solutions on mucociliary clearance in the therapy of acute bacterial rhinosinusitis in vivo. Laryngoscope 2002;112: 320-325. (Pubitemid 34135879)
31. Luo Z, Han D, Xiaohong S, Kuiji W, Hong W. Effect of Oxymetazoline on healthy human nasal ciliary beat frequency measured with high-speed digital microscopy and mucociliary transport time. Ann Otol Rhinol Laryngol 2008; 117: 127-133.
32. Möller W, Häussinger K, Winkler-Heil R, et al. Mucociliary and long-term particle clearance in the airways of healthy non-smokers. J Appl Physiol 2004; 97: 2200-2206.
33. 99m-DTPA: an alternative method to assess lung epithelial transport. J Nucl Med 1990; 31: 441-449.
34. 99mTc DTPA in respiratory tract mucus glycoprotein from patients with chronic bronchitis. Thorax 1988; 43: 669-673.
35. 99mTc-DTPA from the bronchial mucosa. Am Rev Respir Dis 1989; 139: 11321138.
36. Van As A, Webster I. The morphology of mucus in mammalian pulmonary airways. Environ Res 1974; 7: 1-12.
37. 37. Durand M, Rusch P, Granjon D, et al. Preliminary study of the deposition of aerosol in the maxillary sinuses using a plastinated model. J Aerosol Med 2001; 14: 83-93. (Pubitemid 32428973)
38. 38. Schroeter JD, Kimbell JS, Asgharian B. Analysis of particle deposition in the turbinate and olfactory regions using a human nasal computational fluid dynamics model. J Aerosol Med 2006; 19: 301313. (Pubitemid 44735388)
39. 39. Knipping S, Holzhausen H, Riederer A, Bloching M. Cystic fibrosis: ultrastructural changes of nasal mucosa. Eur Arch Otorhinolaryngol 2007; 264: 1413-1418. (Pubitemid 350119681)
40. Lundberg JO, Maniscalo M, Sofia M, Lundblad L, Weitzberg E. Humming, Nitric Oxide, and Paranasal Sinus Obstruction. JAMA 2003; 289: 302-303.